title: Pituitary-adrenocortical hyperfunction and intolerance to fluvoxamine, a selective serotonin uptake inhibitor.
abstract: Of nine nonsuppressors on the dexamethasone suppression test (DST), five (56%) developed intolerable side effects during treatment with fluvoxamine, a new serotonin uptake inhibiting antidepressant, compared with three of 24 suppressors (13%).
authors.forename: W A
authors.initials: WA
authors.lastname: Brown
authors.forename: M
authors.initials: M
authors.lastname: Arato
authors.forename: R
authors.initials: R
authors.lastname: Shrivastava
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D003907:Dexamethasone; D004311:Double-Blind Method; D005260:Female; D016666:Fluvoxamine; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008297:Male; D009325:Nausea / Q000139:chemically induced; D010091:Oximes / Q000009:adverse effects*; D012702:Serotonin Antagonists / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000928:Antidepressive Agents; D010091:Oximes; D012702:Serotonin Antagonists; D003907:Dexamethasone; D016666:Fluvoxamine; D006854:Hydrocortisone